|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STOX2 |
Gene summary for STOX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STOX2 | Gene ID | 56977 |
| Gene name | storkhead box 2 | |
| Gene Alias | STOX2 | |
| Cytomap | 4q35.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9P2F5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56977 | STOX2 | CCI_1 | Human | Cervix | CC | 1.99e-12 | 1.05e+00 | 0.528 |
| 56977 | STOX2 | CCI_3 | Human | Cervix | CC | 6.58e-16 | 1.05e+00 | 0.516 |
| 56977 | STOX2 | CCII_1 | Human | Cervix | CC | 7.34e-11 | 5.60e-01 | 0.3249 |
| 56977 | STOX2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.60e-04 | 4.17e-01 | 0.0338 |
| 56977 | STOX2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.69e-02 | -1.29e-01 | 0.294 |
| 56977 | STOX2 | A014-C-108 | Human | Colorectum | FAP | 2.77e-14 | 8.54e-01 | -0.124 |
| 56977 | STOX2 | A002-C-114 | Human | Colorectum | FAP | 4.41e-03 | 5.04e-01 | -0.1561 |
| 56977 | STOX2 | A015-C-202 | Human | Colorectum | FAP | 1.01e-27 | 8.51e-01 | -0.0849 |
| 56977 | STOX2 | A018-E-020 | Human | Colorectum | FAP | 5.39e-10 | 7.48e-01 | -0.2034 |
| 56977 | STOX2 | AEH-subject1 | Human | Endometrium | AEH | 1.12e-18 | 4.41e-01 | -0.3059 |
| 56977 | STOX2 | AEH-subject2 | Human | Endometrium | AEH | 1.29e-05 | 2.97e-01 | -0.2525 |
| 56977 | STOX2 | AEH-subject3 | Human | Endometrium | AEH | 6.60e-12 | 3.52e-01 | -0.2576 |
| 56977 | STOX2 | AEH-subject5 | Human | Endometrium | AEH | 1.16e-03 | 2.18e-01 | -0.2953 |
| 56977 | STOX2 | EEC-subject1 | Human | Endometrium | EEC | 1.80e-13 | 4.54e-01 | -0.2682 |
| 56977 | STOX2 | EEC-subject2 | Human | Endometrium | EEC | 1.42e-04 | 2.81e-01 | -0.2607 |
| 56977 | STOX2 | EEC-subject3 | Human | Endometrium | EEC | 2.24e-03 | 2.66e-01 | -0.2525 |
| 56977 | STOX2 | TD9 | Human | Lung | IAC | 8.97e-03 | 6.13e-01 | 0.088 |
| 56977 | STOX2 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 2.70e-05 | 8.95e-01 | -0.1406 |
| 56977 | STOX2 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.23e-04 | 8.60e-01 | -0.1408 |
| 56977 | STOX2 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 4.35e-03 | 7.17e-01 | -0.138 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
| GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
| GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
| GO:00075654 | Cervix | CC | female pregnancy | 43/2311 | 193/18723 | 7.62e-05 | 1.04e-03 | 43 |
| GO:00447064 | Cervix | CC | multi-multicellular organism process | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
| GO:00601353 | Cervix | CC | maternal process involved in female pregnancy | 15/2311 | 62/18723 | 7.30e-03 | 3.92e-02 | 15 |
| GO:0001890 | Colorectum | AD | placenta development | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:0061458 | Colorectum | AD | reproductive system development | 116/3918 | 427/18723 | 1.11e-03 | 1.01e-02 | 116 |
| GO:0048608 | Colorectum | AD | reproductive structure development | 114/3918 | 424/18723 | 1.78e-03 | 1.47e-02 | 114 |
| GO:00018902 | Colorectum | MSS | placenta development | 51/3467 | 144/18723 | 1.10e-06 | 3.77e-05 | 51 |
| GO:00614582 | Colorectum | MSS | reproductive system development | 115/3467 | 427/18723 | 9.86e-06 | 2.39e-04 | 115 |
| GO:00486082 | Colorectum | MSS | reproductive structure development | 113/3467 | 424/18723 | 1.94e-05 | 4.18e-04 | 113 |
| GO:0001893 | Colorectum | MSS | maternal placenta development | 13/3467 | 35/18723 | 7.38e-03 | 4.68e-02 | 13 |
| GO:00018903 | Colorectum | FAP | placenta development | 38/2622 | 144/18723 | 6.22e-05 | 1.21e-03 | 38 |
| GO:00614583 | Colorectum | FAP | reproductive system development | 85/2622 | 427/18723 | 4.30e-04 | 5.13e-03 | 85 |
| GO:00486083 | Colorectum | FAP | reproductive structure development | 84/2622 | 424/18723 | 5.40e-04 | 6.10e-03 | 84 |
| GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
| GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
| GO:00018909 | Endometrium | AEH | placenta development | 39/2100 | 144/18723 | 1.07e-07 | 5.20e-06 | 39 |
| GO:00075655 | Endometrium | AEH | female pregnancy | 43/2100 | 193/18723 | 7.52e-06 | 1.80e-04 | 43 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STOX2 | SNV | Missense_Mutation | novel | c.2462A>T | p.Asn821Ile | p.N821I | Q9P2F5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| STOX2 | SNV | Missense_Mutation | c.2364G>T | p.Lys788Asn | p.K788N | Q9P2F5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.058) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| STOX2 | SNV | Missense_Mutation | novel | c.9N>C | p.Lys3Asn | p.K3N | Q9P2F5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.981) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| STOX2 | SNV | Missense_Mutation | c.233N>A | p.Leu78His | p.L78H | Q9P2F5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| STOX2 | insertion | Nonsense_Mutation | novel | c.1629_1630insAGATAACTTCATCATGCACAGCAACACAAACGT | p.Arg543_Ala544insArgTerLeuHisHisAlaGlnGlnHisLysArg | p.R543_A544insR*LHHAQQHKR | Q9P2F5 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| STOX2 | insertion | In_Frame_Ins | novel | c.2464_2465insAACAAAGCCAAGGAGAGATCCAGG | p.Leu822delinsGlnGlnSerGlnGlyGluIleGlnVal | p.L822delinsQQSQGEIQV | Q9P2F5 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| STOX2 | insertion | Nonsense_Mutation | novel | c.1627_1628insGAACACAAACGTGCTCGAGTCCCACTTCCCCATGACACCAGAAT | p.Ala544ThrfsTer11 | p.A544Tfs*11 | Q9P2F5 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| STOX2 | insertion | Frame_Shift_Ins | novel | c.1585_1586insCTTCATCATTGAACACAAAGGAGATAACTTCATC | p.Asp529AlafsTer23 | p.D529Afs*23 | Q9P2F5 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| STOX2 | insertion | Frame_Shift_Ins | novel | c.566_567insATTTTTCATTTTTCTCTCATTTAAA | p.Thr190PhefsTer57 | p.T190Ffs*57 | Q9P2F5 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| STOX2 | insertion | Frame_Shift_Ins | novel | c.665_666insTCCATTTTCCAAAAGACAGAGAC | p.Lys223ProfsTer30 | p.K223Pfs*30 | Q9P2F5 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |